1. ZENIQUIN US Prescribing Information. NADA #141-151. Zoetis Inc, 2001. 2. Sheer M. Concentrations of active ingredient in the serum and in tissues after oral and parenteral administration of Baytril. Vet Med Rev. 1987;2:104-118. 3. Blaser J, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054-1060. 4. Stegmann M, et al. Kinetics of antibacterial activity after administration of enrofloxacin in dog serum and skin: in vitro susceptibility of field isolates. In Proceedings. 2nd International Veterinary Symposium of Fluoroquinolones. Compend Contin Educ Pract Vet. 1996;18(suppl):30-34. 5. Dicural® US Prescribing Information. NADA #141-096. Overland Park, KS: Fort Dodge Animal Health, 1997. 6. Orbax® US Prescribing Information. NADA #141-081. Union, NJ: Schering-Plough Animal Health Corporation, 1997.
IMPORTANT SAFETY INFORMATION: Important Safety Information: ZENIQUIN is not recommended for use in immature cats or dogs during the rapid growth phase, or in cats or dogs known to be hypersensitive to fluoroquinolones. People with a history of hypersensitivity to fluoroquinolones should avoid this product.
For more safety information, refer to the full prescribing information.